These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 33952452

  • 1. Combined Targeting of AKT and mTOR Synergistically Inhibits Formation of Primary Colorectal Carcinoma Tumouroids In Vitro: A 3D Tumour Model for Pre-therapeutic Drug Screening.
    Nörz D, Mullins CS, Smit DJ, Linnebacher M, Hagel G, Mirdogan A, Siekiera J, Ehm P, Izbicki JR, Block A, Thastrup O, Jücker M.
    Anticancer Res; 2021 May; 41(5):2257-2275. PubMed ID: 33952452
    [Abstract] [Full Text] [Related]

  • 2. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M.
    Mol Cancer; 2012 Nov 20; 11():85. PubMed ID: 23167739
    [Abstract] [Full Text] [Related]

  • 3. Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo.
    Schulte A, Ewald F, Spyra M, Smit DJ, Jiang W, Salamon J, Jücker M, Mautner VF.
    Int J Mol Sci; 2020 Feb 24; 21(4):. PubMed ID: 32102484
    [Abstract] [Full Text] [Related]

  • 4. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jücker M.
    Int J Cancer; 2013 Nov 24; 133(9):2065-76. PubMed ID: 23588885
    [Abstract] [Full Text] [Related]

  • 5. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
    Smit DJ, Cayrefourcq L, Haider MT, Hinz N, Pantel K, Alix-Panabières C, Jücker M.
    Cells; 2020 Sep 20; 9(9):. PubMed ID: 32962206
    [Abstract] [Full Text] [Related]

  • 6. Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.
    Ou DL, Lee BS, Lin LI, Liou JY, Liao SC, Hsu C, Cheng AL.
    Mol Cancer; 2014 Jan 03; 13():2. PubMed ID: 24387108
    [Abstract] [Full Text] [Related]

  • 7. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma.
    Imura Y, Yasui H, Outani H, Wakamatsu T, Hamada K, Nakai T, Yamada S, Myoui A, Araki N, Ueda T, Itoh K, Yoshikawa H, Naka N.
    Mol Cancer; 2014 Aug 07; 13():185. PubMed ID: 25098767
    [Abstract] [Full Text] [Related]

  • 8. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 9. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F.
    Int J Cancer; 2013 Nov 31; 133(9):2089-101. PubMed ID: 23629727
    [Abstract] [Full Text] [Related]

  • 10. Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.
    Djukom C, Porro LJ, Mrazek A, Townsend CM, Hellmich MR, Chao C.
    Pancreas; 2014 Jan 31; 43(1):88-92. PubMed ID: 24263107
    [Abstract] [Full Text] [Related]

  • 11. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
    Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA.
    PLoS One; 2010 Nov 29; 5(11):e14124. PubMed ID: 21124782
    [Abstract] [Full Text] [Related]

  • 12. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
    von Achenbach C, Weller M, Kaulich K, Gramatzki D, Zacher A, Fabbro D, Reifenberger G, Szabó E.
    J Neurochem; 2020 May 29; 153(4):510-524. PubMed ID: 31618458
    [Abstract] [Full Text] [Related]

  • 13. Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.
    Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, Tan AC, Messersmith WA, Eckhardt SG, Leong S.
    PLoS One; 2014 May 29; 9(11):e113037. PubMed ID: 25401499
    [Abstract] [Full Text] [Related]

  • 14. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
    Sandhöfer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiß V, Carlet M, Walter G, Hinrichsen T, Wachter O, Grunert M, Schneider S, Subklewe M, Dufour A, Fröhling S, Klein HG, Hiddemann W, Jeremias I, Spiekermann K.
    Leukemia; 2015 Apr 29; 29(4):828-38. PubMed ID: 25322685
    [Abstract] [Full Text] [Related]

  • 15. Novel PI3K/Akt/mTOR signaling inhibitor, W922, prevents colorectal cancer growth via the regulation of autophagy.
    Wang J, Liang D, Zhang XP, He CF, Cao L, Zhang SQ, Xiao X, Li SJ, Cao YX.
    Int J Oncol; 2021 Jan 29; 58(1):70-82. PubMed ID: 33367926
    [Abstract] [Full Text] [Related]

  • 16. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
    Wen Q, Wang W, Luo J, Chu S, Chen L, Xu L, Zang H, Alnemah MM, Ma J, Fan S.
    Oncotarget; 2016 May 10; 7(19):27787-801. PubMed ID: 27050281
    [Abstract] [Full Text] [Related]

  • 17. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
    Alqurashi N, Hashimi SM, Alowaidi F, Ivanovski S, Wei MQ.
    Oncol Rep; 2018 Aug 10; 40(2):1083-1092. PubMed ID: 29845289
    [Abstract] [Full Text] [Related]

  • 18. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
    Korets SB, Musa F, Curtin J, Blank SV, Schneider RJ.
    Gynecol Oncol; 2014 Feb 10; 132(2):468-73. PubMed ID: 24316308
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C, Gao D, Guo K, Kang X, Jiang K, Sun C, Li Y, Sun L, Shu H, Jin G, Sun H, Wu W, Liu Y.
    BMC Cancer; 2012 May 04; 12():166. PubMed ID: 22559167
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.